I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

Squamous NSCLC

ErbB mutations in patients with squamous NSCLC: a subanalysis of LUX-Lung 8

In a genetic analysis of 245 patients with squamous cell carcinoma (SqCC)of the lung  from the LUX-Lung 8 study, 53 (21.6%) had tumours with at least one ErbB Family mutation.1 Progression-free survival (PFS) and overall survival (OS) were longer with afatinib* versus erlotinib in patients with ErbB wild-type tumours (median PFS: 3.5 vs 2.5 months; hazard ratio[HR]=0.69; 95% confidence interval [CI]: 0.51–0.92; p=0.012; median OS: 8.4 vs 6.6 months; HR=0.81; 95% CI: 0.62–1.05; p=0.115). These effects were more pronounced in afatinib-treated patients with ErbB mutation-positive tumours versus afatinib-treated patients without ErbB mutations (median PFS: 4.9 vs 3.0 months; HR=0.62; 95% CI: 0.37–1.02; p=0.062; median OS: 10.6 vs 8.1 months; HR=0.75; 95% CI: 0.47–1.17; p=0.206). The most marked effect was seen in 12 patients with HER2 mutations.1 The presence of HER2 mutations predicted favourable PFS (interaction p value = 0.006) and OS (interaction p value = 0.003) with afatinib versus erlotinib.1

Did you find this information useful?

References

1

Goss GD, et al. JAMA Oncol 2018 Jun 14. doi: 10.1001/jamaoncol.2018.0775. [Epub ahead of print].

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: October 2018